GRAIL vs Becton Dickinson
Side-by-side comparison of AI visibility scores, market position, and capabilities
GRAIL develops multi-cancer early detection Galleri test using cell-free DNA methylation to detect signals from 50+ cancer types in a single blood draw; spun off from Illumina in 2024; NHS-Galleri trial enrolling 140,000 participants in the UK.
About
GRAIL is a healthcare company founded in 2016 as an Illumina spinout focused on developing multi-cancer early detection tests using liquid biopsy technology. The company's flagship product Galleri is a blood test that analyzes cell-free DNA methylation patterns to detect cancer signals from over 50 cancer types, many of which lack standard screening tests, enabling detection at early stages when treatment is most effective. GRAIL raised over $3.5B from investors including Amazon and Bristol Myers Squibb and was reacquired by Illumina in 2021 before being spun off again in 2024 as an independent public company following regulatory complications. Galleri has been launched commercially and is being evaluated in large clinical studies including the NHS-Galleri trial in the UK enrolling 140,000 participants. The company represents a transformative approach to oncology that could shift cancer care from reactive treatment toward proactive screening. GRAIL's technology addresses a massive unmet need given that the majority of cancers are diagnosed at late stages when outcomes are poor.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
About
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.